Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Chief Technology Officer Heinrich Röder, DPhil, will present at the 6th Oncology Biomarkers Conference as part of the Biomarker Summit 2013, being held March 20-22 in San Francisco. Dr. Röder will discuss how Biodesix’ high-throughput mass spectrometry technology, Deep MALDI™, is used to generate protein signatures for specific questions in oncology.